BSB 1001
Alternative Names: BSB-1001; miHA 1 targeting TCR T cell therapy - BlueSphere BioLatest Information Update: 18 Jun 2024
At a glance
- Originator BlueSphere Bio
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Leukaemia
Most Recent Events
- 03 Jun 2024 BlueSphere Bio plans phase-I/IIa TCX-101 trial for Leukemia (Second-line therapy or greater, Combination therapy) in 4Q2024 (Parenteral)
- 03 Jun 2024 US FDA approves IND application for a phase-I/IIa TCX-101 trial for BSB 1001 for Leukemia (Second-line therapy or greater)
- 30 May 2024 BlueSphere Bio plans a phase I/Ib trial for Acute myeloid leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma and Myeloidysplastic syndromes and anticipates dosing its first patient in early 2025